Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-29
2008-01-29
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S244000, C514S280000, C514S081000, C514S265100, C514S052000, C536S026700, C536S027200
Reexamination Certificate
active
10520925
ABSTRACT:
The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such thionucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the thionucleoside compounds of the present invention.
REFERENCES:
patent: 6777395 (2004-08-01), Bhat et al.
patent: 6812219 (2004-11-01), LaColla et al.
patent: 2003/0050229 (2003-03-01), Sommadossi et al.
patent: 2003/0060400 (2003-03-01), LaColla et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2004/0072788 (2004-04-01), Bhat et al.
patent: 2004/0097461 (2004-05-01), Sommadossi et al.
patent: 2004/0147464 (2004-07-01), Roberts et al.
patent: 2004/0259934 (2004-12-01), Olsen et al.
patent: WO 9401117 (1994-01-01), None
patent: WO01/90121 (2001-11-01), None
patent: WO01/92282 (2001-12-01), None
patent: WO02/32920 (2002-04-01), None
patent: WO02/057287 (2002-07-01), None
patent: WO02/057425 (2002-07-01), None
patent: WO03/051899 (2003-06-01), None
patent: WO03/062255 (2003-07-01), None
patent: WO03/062256 (2003-07-01), None
patent: WO03/068244 (2003-08-01), None
patent: WO03/093290 (2003-11-01), None
patent: WO03/105770 (2003-12-01), None
patent: WO2004/000858 (2003-12-01), None
patent: WO2004/002422 (2004-01-01), None
patent: WO2004/002999 (2004-01-01), None
patent: WO2004/007512 (2004-01-01), None
patent: WO2004/009020 (2004-01-01), None
patent: WO2004/028481 (2004-04-01), None
patent: WO2004/046331 (2004-06-01), None
patent: WO2004/065398 (2004-08-01), None
patent: WO2004/072090 (2004-08-01), None
M. Bobek, R. L. Whistler, and A. Bloch J. Med. Chem.; 1972; 15(2) pp. 168-171.
Anne B. Eldrup et al., “Structure-Activity Relationship of Heterobase-Modified 2′-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication”, J. Med.Chem., vol. 47, pp. 5284-5297 (2004).
Anne B. Eldrup et al., “Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase”, J. Med.Chem., vol. 47, pp. 2283-2295 (2004).
David B. Olsen et al., “A 7-Deaza-Adenosine Analog is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties”, Antimicrobial Agents and Chemotherapy, vol. 48, No. 10, pp. 3944-3953 (2004).
Per Hoffmann et. al., “Recent Patents on Experimental Therapy for Hepatitis C Virus Infection”, Expert Opin. Ther. Patents, vol. 13(11), pp. 1707-1723, (2003).
Volker Brass et al., “Recent Developments in Target Identification against Hepatitis C Virus”, Expert Opin. Ther. Targets, vol. 8(4), pp. 295-307, (2004).
Murai, Y. et al. “A Synthesis and an X-Ray Analysis of 2′-C-, 3′-C-, and 5′-C-Methylsangivamycins”, Heterocycles, 1992, vol. 33, pp. 391-404.
Iimori, T. et al. “A study on conformationally restricted sangivamycins and their inhibitory abilities of protien kinases”, Oxford University Press, 1992, pp. 169-170.
Bhat Balkrishen
Cook Phillip Dan
Olsen David B.
Berch Mark L.
Durette Philippe L.
Heber Sheldon O.
Isis Pharmaceuticals , Inc.
Merck & Co. , Inc.
LandOfFree
Thionucleoside derivatives as inhibitors of RNA-dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thionucleoside derivatives as inhibitors of RNA-dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thionucleoside derivatives as inhibitors of RNA-dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3925041